

Molecular Recognition in Helix-Loop-Helix and Helix-Loop-Helix-Leucine Zipper Domains

DESIGN OF REPERTOIRES AND SELECTION OF HIGH AFFINITY LIGANDS FOR NATURAL PROTEINS*

Received for publication, November 25, 2002, and in revised form, December 27, 2002
Published, JBC Papers in Press, January 3, 2003, DOI 10.1074/jbc.M211991200

Roberta Ciarapica‡§, Jessica Rosati‡§, Gianni Cesareni¶, and Sergio Nasi‡||

From the ‡Istituto di Biologia and Patologia Molecolari Consiglio Nazionale delle Ricerche, Università La Sapienza, 00185 Roma and ¶Dipartimento di Biologia, Università Tor Vergata, 00133 Roma, Italy

Helix-loop-helix (HLH) and helix-loop-helix-leucine zipper (HLHZip) are dimerization domains that mediate selective pairing among members of a large transcription factor family involved in cell fate determination. To investigate the molecular rules underlying recognition specificity and to isolate molecules interfering with cell proliferation and differentiation control, we assembled two molecular repertoires obtained by directed randomization of the binding surface in these two domains. For this strategy we selected the Heb HLH and Max Zip regions as molecular scaffolds for the randomization process and displayed the two resulting molecular repertoires on λ phage capsids. By affinity selection, many domains were isolated that bound to the proteins Mad, Rox, MyoD, and Id2 with different levels of affinity. Although several residues along an extended surface within each domain appeared to contribute to dimerization, some key residues critically involved in molecular recognition could be identified. Furthermore, a number of charged residues appeared to act as switch points facilitating partner exchange. By successfully selecting ligands for four of four HLH or HLHZip proteins, we have shown that the repertoires assembled are rather general and possibly contain elements that bind with sufficient affinity to any natural HLH or HLHZip molecule. Thus they represent a valuable source of ligands that could be used as reagents for molecular dissection of functional regulatory pathways.

The helix-loop-helix (HLH)¹ proteins, with over 250 representatives in organisms ranging from yeast to man, are one of the most important and versatile families of eukaryotic transcription factors and are involved in diverse processes such as lineage commitment and differentiation, angiogenesis, cell cycle, growth control, and apoptosis (1–3). They are characterized by a highly conserved structural motif organized in a DNA binding sequence, the basic region, and a dimerization domain, either HLH (helix-loop-helix) or HLHZip (helix-loop-helix-

leucine zipper). They associate in homo- and heterodimeric complexes that recognize E-box sequences (CANNTG) on DNA, recruit cofactors, and activate or repress transcription of many genes (1–3). Selective dimerization is a regulatory mechanism that allows the expansion of their functional repertoire and also a fine tuning of gene expression by competition of different complexes able to bind the same DNA target sequences. The bHLHZip protein Max, constitutively expressed, is able to homodimerize as well as to heterodimerize with the other bHLHZip factors of the Max network (Myc, Mad1–4, Mnt/Rox), in which expression is regulated and which work only in association with Max (2, 3). *Myc*, one of the most frequently altered genes in human cancer, induces proliferation, growth, and apoptosis but inhibits differentiation (2–5). Mad and Mnt proteins, although possessing DNA binding specificities quite similar to Myc, have only partially overlapping, and frequently opposite, biological functions such as the ability to promote cell survival and differentiation. Similar to Max, among the factors lacking the Zip region, the omnipresent E-proteins (Heb, E47, E12, E2-2) also bind DNA as homodimers (1). The numerous tissue-specific bHLH proteins (MyoD, SCL/Tal, Mash, and many others) poorly homodimerize but require the association with E-proteins to bind DNA and exert their biological functions. HLH proteins lacking a basic region, such as the mammalian Id1–Id4, impose another level of regulation by sequestering E-proteins in dimers that are unable to bind to DNA (1). Understanding molecular recognition is a step toward a rational design of molecules that interfere with HLH protein function. In this regard, we showed that it is possible to inhibit Myc tumorigenic capacity by means of Omomyc, a mutant bHLHZip domain, obtained by changing four residues in the Myc Zip region (6). Omomyc sequesters Myc in complexes unable to bind DNA, preventing transcriptional activation, enhancing repression, potentiating apoptosis (7), and suppressing Myc-induced papillomatosis.²

To gain insight into the rules of protein-protein recognition and to isolate mutant domains capable of functional interference, repertoires of HLH and HLHZip domains were designed, exposed on λ phage head, and screened by *in vitro* panning. Several domains that bound with different affinity to MyoD, Id2, Mad-1, and Rox were isolated; their comparison allowed us to elucidate the contribution of different amino acid residues to the stability and specificity of monomer-monomer interactions. These repertoires are a source of potential competitive inhibitors, useful for functional dissection and for drug design.

EXPERIMENTAL PROCEDURES

Phage, Plasmids, and GST Fusion Proteins—DNA sequences encoding Max bHLHZip (Ala²² to Leu¹⁰²) and repertoires of HLH and bHL-

* This work was funded by a grant from the Associazione Italiana Ricerca sul Cancro. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ These two authors contributed equally to the work.

|| To whom correspondence should be addressed: Università La Sapienza, Istituto di Biologia e Patologia Molecolari CNR, Piazzale Aldo Moro 5, 00185 Roma, Italy. Tel.: 39-0649912241; Fax: 39-0649912500; E-mail: sergio.nasi@uniroma1.it.

¹ The abbreviations used are: HLH, helix-loop-helix; bHLH, basic helix-loop-helix region; Zip, leucine zipper; GST, glutathione *S*-transferase; HRP, horseradish peroxidase; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline.

² L. Soucek, S. Nasi, and G. Evan, submitted for publication.

HZip domains were PCR amplified and inserted into the λ D4 vector DNA, between *SpeI* and *NotI* restriction sites at the 3'-end of a second copy of the D-gene (8). pGEX-2T (Amersham Biosciences) expression plasmids containing GST fusions to human Id2, mouse MyoD, human Max, baboon Mad (amino acids 36–221) and mouse Rox (amino acids 197–346) were introduced into BL21 *E. coli* cells. Cells were grown at 37 °C to an $A_{600} \sim 0.5$ and induced with 0.1 mM isopropyl- β -D-thiogalactopyranoside for 3 h at 37 °C (MyoD, Id2) or at room temperature (Max, Mad, Rox). After lysis in the presence of 1% Triton X-100, fusion proteins were affinity-purified on glutathione-Sepharose beads (Amersham Biosciences) and analyzed by PAGE.

Construction of HLH and bHLHZip Libraries—A HLH domain repertoire was obtained by PCR amplification of the *heb* gene HLH domain sequence with two degenerate primers that contained *SpeI* and *NotI* sites: HLH-*SpeI*, 5'-GAACGCCTAGTGTGCGGGATVTTAATSWMG-CATTSRAMRMSCTTRRGCGADTSDBTCAG-3'; HLH-*NotI*, 5'GTTCTCGCGCCGCGCTGTGCTACGACTAAGGATGWMTCGTWYGGCTTGATGAAGARTGAGGABTTTTGDTWGGGG-3' (sequence symbols for degenerate oligonucleotides are: V = ACG, S = GC, W = AT, M = AC, R = AG, D = ATG, B = GCT, K = TG, Y = CT). The reactions, containing 100 ng of template DNA, 2 μ M oligonucleotide primers, and 4.5 *Pfu* polymerase units, were cycled 35 times at two different annealing temperatures (45 and 52 °C). The resulting products were mixed to guarantee the highest level of variability.

A bHLHZip repertoire was generated by two successive PCR amplifications on a *max* bHLHZip template. A leucine zipper (Zip) repertoire was obtained in the first reaction with the two degenerate primers: Lz, 5'-ACAGAGTATATCCAGTATATGSRRAAGGVAMRASCACACACWC-MDACAAVWMRWAGACGAC-3'; and Lz-*NotI*: 5'-CAGTGAATTCCC-GGGCGCCGCGCTGTGCTACGACTAAGGATGWMTCGTWYGGCTTGATGAAGARTGAGGABTTTTGDTWGGGG-3'. The Zip repertoire was used as 3'-primer for the second PCR reaction, whereas an oligonucleotide matching the *max* basic region (Max-*SpeI*, 5'-TGGGTAAGTGTGCTGACAAACGGGCT-3') served as 5'-primer, creating a bHLHZip repertoire with degenerate Zip regions linked to Max bHLH. Following hot start with *Taq* polymerase (Sigma), the reaction was cycled 35 times (1 min at 95 °C, 1 min at 55 °C, 1 min at 72 °C) followed by a 7-min elongation step.

DNA of both repertoires was digested with *SpeI* and *NotI* restriction enzymes and gel-purified. 20–30 ng of purified insert was ligated to 2 μ g of *SpeI/NotI*-digested λ D4 vector DNA, purified by isopropanol precipitation. The ligation products were phenol/chloroform-extracted, isopropanol-precipitated, and *in vitro* packaged with a Gigapack III Gold kit (Stratagene). The libraries were amplified once by infection of *Escherichia coli* BB4 cells, plated onto LB-agarose plates, and grown for 6–8 h at 37 °C. Phage was eluted overnight at 4 °C with SM buffer (100 mM NaCl, 10 mM MgSO₄, 35 mM Tris-HCl, pH 7.5), precipitated with polyethylene glycol, and suspended at 1×10^{10} pfu/ml.

Panning with GST Fusions to Target HLH Proteins—Affinity selection of phage libraries was performed with GST fusion Id2, MyoD, Mad, and Rox proteins. Phage particles (1×10^9 pfu) were incubated for 1 h at 4 °C with 10 μ g of purified GST fusion protein, immobilized on glutathione-Sepharose beads, and preincubated for 2 h in PBS, 3% bovine serum albumin. The beads were washed repeatedly in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.5% Tween 20 and suspended in 100 μ l of SM buffer. Bound phage was recovered by infection of BB4 cells and plated onto 143-mm dishes. Phage was eluted with SM, titered, and subjected to two more biopanning rounds.

Filter Immunoscreeing of Phage Clones—Lysates were prepared from single phage plaques, concentrated by polyethylene glycol precipitation, and titered. 1×10^7 pfu from each phage stock were spotted onto nitrocellulose membrane (Nitroplus, Micron Separation Inc.), which was incubated at room temperature for 2 h in blocking buffer (PBS, 5% milk, 0.1% Nonidet P-40) and again for 2 h with 1 μ g/ml GST target protein in the same buffer. After washing in PBS, 0.1% Triton, membranes were incubated for 1 h at room temperature with anti-GST goat serum (Amersham Biosciences, 1:1000) and preadsorbed on bacterial lysate, followed by horseradish peroxidase (HRP)-conjugated anti-goat IgG (1:10000), washed, and developed with an enhanced chemiluminescence kit (ECL, from Amersham Biosciences).

ELISA—Multiwell plates (Nunc) were coated overnight at 4 °C with 100 μ l of anti-GST goat serum (5 μ g/ml in PBS), washed in PBS, 0.05% Tween, and incubated in PBS, 0.05% Tween, 5% milk for 1 h at 37 °C. 0.5 μ g of GST fusion protein was added to each well, for 1 h at room temperature. After washing, phage (10^8 pfu/well) was added and incubated for 1 h at room temperature. The plates were washed with PBS, 0.05% Tween, incubated for 1 h at room temperature with anti- λ phage rabbit IgG (1:1000, courtesy of R. Cortese, Istituto di Ricerca di Biologia Molecolare, Pomezia (Rome)), and then incubated with HRP-

conjugated protein A (1:10000, Sigma). Reactions were revealed by adding 100 μ l/well tetramethylbenzidine solution (Promega), and the absorbance (A) values were recorded by an automated ELISA reader set at 450 nm. All assays were repeated at least three times. The reported values are in arbitrary units, calculated by normalization to the background interaction with GST and to the interaction of empty vector phage to GST, according to the following formula: $[A_{\text{phage clone-GST fusion}} - (A_{\text{vector-GST fusion}} - A_{\text{vector-GST}})]/A_{\text{phage clone-GST}}$.

DNA Sequencing—Phage DNA inserts were PCR-amplified from 1 μ l of phage lysate with two primers flanking the *SpeI* and *NotI* cloning sites: 5'-CACGTTCGGTTATGAGGATGT-3' and 5'-ATGTATCAGTGCCTAGC-3'. The PCR products were purified from agarose gel using the Concert™ Rapid PCR Purification system (Invitrogen), and their sequences were determined with an ABI-3700 automated sequencer.

Western Blotting—Phage was lysed by boiling for 5 min in 2 \times SDS-gel sample buffer; proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes (Amersham Biosciences). Blots were incubated for 1 h at room temperature with anti-D-protein (1:1500, courtesy of R. Cortese) or anti-Max (Santa Cruz C-124; 1:5000) antibodies followed by HRP-protein A (1:10000) and developed with an Amersham Biosciences ECL kit.

RESULTS

Display of Max bHLHZip Domain on λ Phage—To identify the most appropriate vector for the display of HLH and HLHZip domain repertoires, we tested both filamentous phage vectors, successfully exploited for the construction of peptide or antibody repertoires (9, 10), and λ phage, reported to be generally more suitable for exposing large polypeptides (11–13). The DNA sequence encoding Max bHLHZip was cloned into the three filamentous phage vectors pC89, pC178, and pHENA, to obtain N-terminal fusions to pVIII or pIII coat proteins (14, 15) and into the λ display vector 4 (λ D4) to display fusions to the D-protein C terminus (8, 16). We asked which vector would efficiently display Max bHLHZip and allow its binding to a natural dimerization partner, the GST fusion protein Mad (2). We found that only the λ vector particles were able to incorporate the D-Max chimeric capsid protein in an amount sufficient for immunological detection in Western blots (Fig. 1A). Furthermore, in a simulated panning experiment, we were able to selectively enrich λ phages displaying Max by 1000-fold after three cycles of affinity purification over glutathione resin containing GST-Mad (Fig. 1B). Thus, λ D4 was selected for the display of domain repertoires.

Design of HLH and HLHZip Repertoires—Repertoires were constructed by mutating only selected amino acids within the scaffold domain sequences, because the library size necessary to fully represent the diversity obtainable by random variations would rapidly saturate the possibilities of phage display libraries. The sequences of Max HLHZip and Heb E-protein HLH were taken as scaffolds for the two domain families (Figs. 2 and 3) because of their dimerization versatility and because of the availability of either their high resolution crystallographic structure (Max (17, 18)) or that of a close relative (E47, an E-protein that shares a high degree of homology with Heb (19)). The amino acid sequences of a large number of HLH and HLHZip domains from different organisms were aligned and the occurrence of different amino acids in each position determined. Strictly conserved residues, likely to be essential for domain stability, were maintained constant in the repertoire design, whereas the artificial repertoire variation was directed at residues that presented natural variability or were shown to be involved in contacts between subunits in the dimeric structures of Max, E47, MyoD, USF, PHO4, and SREBP (17–23). Because a complete randomization of these residues could not be represented fully in a phage display library, only the amino acids found in natural proteins were included in the design. In this way, diversity was reduced to about 7×10^8 combinations, representing a large fraction of the variability observed in natural domains (Figs. 2B and 3B).




FIG. 1. Display on λ phage coat and affinity selection of Max bHLHZip domain. *A*, Western blots. Phage (10^5 pfu/lane) proteins were probed with Max (*left*) and phage head D-protein (*right*) antisera. λ , empty D4 vector phage; λ -Max, phage containing a D coat protein-Max bHLHZip domain fusion (27 kDa); GST-Max, GST-Max fusion protein (47 kDa). *B*, plaque immunoscreening. λ -Max, at a 1:10000 ratio with empty vector phage, was subjected to three panning cycles with immobilized GST-Mad. Plaques were screened with Max antibodies. The amount of phage exposing Max bHLHZip was enriched by ~ 1000 -fold after the third cycle.

In more detail, in the bHLHZip repertoire the degeneration was restricted to the 29-amino acid-long Zip region, which previously had been shown to dictate recognition specificity among bHLHZip domains (6, 24–26). We introduced variations at 13 amino acids occupying the *a*, *d*, *e*, and *g* positions of the helical wheel (Fig. 3*B*). These residues represent the interface between the two Zip monomers, whereas the *b*, *c*, and *f* positions are solvent-exposed and were therefore kept invariant (17, 20, 25, 27).

The 44-amino acid-long HLH domain has a more complex structure (Fig. 2*A*). The helix-loop-helix dimerization motif is a compact four-helix bundle, where the two α -helices package in a coiled-coil only near the carboxyl terminus of the dimer (19). In this case, also residues at *b*, *c*, and *f* positions significantly contribute to the four-helix bundle. Moreover, loop residues, such as Gln²² and Thr²³ in the E-proteins, are involved in intermolecular bonds (19). On the basis of these observations, the 15 positions illustrated in Fig. 2*B* were degenerated in the designed repertoire. Among the residues that were left unchanged there are those at positions 8, 24, 28, 35, 38 in which mutation had previously been shown to impair dimerization (28).

Degenerate DNA sequences encoding the designed HLH and bHLHZip domain repertoires were synthesized by PCR and cloned in the display vector λ D4 as fusions to the D capsid protein C terminus (8). Following *in vitro* packaging, $\sim 2 \times 10^6$ and $\sim 1 \times 10^6$ pfu were obtained for the HLH and bHLHZip libraries, respectively. By PCR amplification and sequencing of DNA inserts from randomly chosen phage plaques, we found that $\sim 80\%$ of the phages in each library were recombinant, and that each one contained an insert incorporating from 5 to 10 amino acid changes when compared with the natural scaffold sequence (data not shown).

Affinity Selection with GST-tagged HLH and HLHZip Domains—GST fusions to MyoD and Id2, or to Mad and Rox, were used as baits for panning the HLH and the HLHZip libraries, respectively. For each experiment, after three rounds of selection, ~ 100 phage clones were amplified, and the interactions with the protein baits were tested by a filter assay. Approximately 10% of the isolated phage clones could be proved to display protein domains that consistently bound the bait. Binding was specific because the clones did not bind GST alone or GST fusions to unrelated protein domains, such as p75 neuro-




FIG. 2. Design of an HLH domain repertoire. **A**, structural overview of E47 bHLH dimers complexed with DNA (19). The first and last residues of the E47 HLH region (Ile³⁵² and Gln³⁹²) are indicated. The subdomains of one of the two monomers are highlighted in different colors: basic region (BR) in green, helix 1 (H1) in fuchsia, loop in gray, and helix 2 (H2) in blue. The amino acid residues mutated in the repertoire are in lighter tones. The arrows denote three mutated helix 1 residues at positions *f*, *b*, and *c* of the helical wheel. They correspond, respectively, to residues Glu³⁵⁴, Arg³⁵⁷, and Glu³⁵⁸ of the E47 sequence, which are on the surface of helix 1, nearest to helix 2' (Glu³⁵⁶, Glu³⁵⁸) or helix 2 (Arg³⁵⁷) (19). **B**, outline of the HLH repertoire. Sequence alignments of the most representative HLH domains, grouped in subfamilies, are shown below the Heb scaffold domain. The most conserved residues are highlighted with the same color scheme that was used for the subdomains. Positions degenerated in the repertoire were numbered as shown above the sequence alignment. Nucleotide composition and encoded amino acids for each degenerate position are shown at the top; the classical *a-b-c-d-e-f-g* heptad repeat of helical structures is indicated.

trophin receptor and amyloid precursor protein cytoplasmic regions. We quantified the interaction to MyoD, Id2, HEB, Rox, Mad, and Max by ELISA, revealing a number of phage clones with high binding affinity (Figs. 4 and 5). The amino acid sequences of HLH(Zip) inserts were deduced from the DNA sequences and aligned to pinpoint the residues responsible for dimerization specificity and affinity. A number of differences were evident in the sequence alignment (Figs. 4B and 5B). The amino acid frequency profiles of the domains with the highest and the lowest affinity for Id2, MyoD, Mad, and Rox are shown in Tables I and II.

The protein domains isolated from the HLH repertoire were shown in ELISA experiments to bind MyoD, Id2, and Heb with different intensities, ranging from 1 to 8 on an arbitrary scale (Fig. 4B and Table I). Id2 was invariably bound more strongly than MyoD, reflecting the different interaction strength between natural E-proteins and the two baits (1, 28). Amino acid alignment showed a preference for many residues of the E-protein consensus sequence, suggesting that these residues increase dimer stability (Fig. 4B and Table I). They include Ile¹, Gly⁹, Met¹¹, and Cys¹² in helix 1, Gln²² and Thr²³ in the loop, and Leu²⁵ and Val³⁴ in helix 2. The sequence glycine, methionine, and cysteine at positions 9, 11, and 12 is a specific motif of E-proteins, which precedes their extra helical turn at the helix 1 C terminus (Fig. 2B (19)). At positions 11 and 12 only a few of the residues present in the repertoire were found in the selected domains; the preference for Cys¹² was stronger than for Met¹¹ (76 versus 53%). All possible amino acids were found at position 9, where glycine occurred with a 65% frequency, and it was strongly preferred by high affinity binders (domains 43M, 72I, 42I, 13I, 98M, 27M, 18I, and 43I). Gly⁹ was present

whenever Ile²⁷ was found (domains 13I, 53I, 98M, 27M), an observation that suggests a possible interaction between residues 9 and 27, two positions involved in intrachain interactions according to HLH modeling studies (30). The positive correlation between a Gly⁹ residue and dimerization strength can be explained by structural similarity to the E47 dimer (19), which shows an intrachain hydrogen bond between Gly⁹ and Gln²², a loop residue present in all selected clones. The four-helix bundle must be stabilized if this interaction is preserved in the mutant domains. A similar argument can also explain the preference for Thr²³, which, in the E47 dimer, interacts with Leu²⁶, a residue not mutated in the repertoire. Thr²³ was found in all domains but two (71I and 37M) that have a Ser residue and are not very strong binders, whereas Pro was never selected. Unlike the majority of the residues, the three negatively charged glutamates found in E-proteins at positions 3, 7, and 39 were either totally absent (Glu³, Glu³⁹) or present (Glu⁷) only in domains that did not strongly interact with MyoD and Id2 (14I, 24I, 30I, 92M; Fig. 4B), whereas hydrophobic or neutral amino acids (Leu, Val, Ala, Pro, Asn, Gln, Thr) were preferred in the domains isolated by panning. This was not because of under-representation, because the glutamates were present at the expected frequency in the HLH repertoire, as indicated by sequencing of random clones (Table I). The three glutamates are involved in E47 dimerization; Glu³ and Glu⁷ are on the surface of helix 1, nearest to helix 2', whereas Glu³⁹, on helix 2, interacts with His^{15'}, on helix 1' (19). It is interesting to remark the E39Q and V34Y substitutions in the 72I domain, a high affinity binder to Id2 and MyoD, because Gln and Tyr are found at the corresponding helix 2 positions in MyoD and Id2 and in the yeast bHLH, Pho4. In the Pho4 dimer,




FIG. 5. Sequence and binding affinity of selected bHLHZip domains. *A*, ribbon representation of Max Zip region (17) depicting the residues that were mutated in the repertoire. Residues, in the same color code as described in Fig. 3 legend, are connected to the amino acid substitutions introduced in the repertoire (yellow). *B*, amino acid sequences and relative binding strengths. Phage clones were affinity selected from the bHLHZip repertoire using GST-Mad and GST-Rox as baits. Dimerization of phage clones and a λ -Max control with Max, Mad, and Rox bHLHZip domains was measured by ELISA. Relative binding strengths, normalized and expressed in arbitrary units (average values \pm S.D. from five independent experiments), are indicated on the left of each clone. The amino acid sequence of Max Zip region, used as scaffold in the repertoire design, is underlined; the residues introduced in each degenerate position are indicated above the Max sequence.

acid residues occurring at positions 3, 7, and 39, allowing the formation of stable heterodimers with MyoD and Id2 in the absence of all three Glu residues. Thus, they appear to destabilize the dimers. Previous work suggested that heterodimers of MyoD with the E12 E-protein are stabilized by attractive pairs formed by Glu³, Glu⁷, and Glu³⁹ residues of E12 with MyoD residues Arg²⁹, Arg³³, and Gln³⁹, respectively (34). Because more stable dimers can be obtained with noncharged amino acids, it seems that the role of the charged Glu residues in the E-protein is to prevent an excessively strong interaction with MyoD or Id2, allowing the physiological partner exchange. Similarly, the presence of histidine at Zip position 8 appears to destabilize dimers and promote partner exchange, because this residue was counter-selected in the high affinity binders to Mad and Rox (Fig. 5B, Table II). Consistent with our findings, Max homodimers were strongly stabilized by the replacement of His⁸ with a leucine and to a lower extent by alanine and tyrosine (31). Leu⁸ is also present in the bHLHZip protein USF, which forms homodimers that are topologically indistinguishable from Max but does not form heterodimers (17). The two *e-g* salt bridges, Myc Glu¹¹-Max Lys¹⁶ and Myc Arg¹⁸-Max Glu²³, contribute to Myc/Max heterodimerization (24, 26). The residues found at positions 16 and 23 in the highest affinity binders to Mad and Rox (*e.g.* domains r27, m52, r45, m20) make either one or both of these electrostatic interactions impossible. Thus they are dispensable for heterodimerization with Mad and Rox, which is consistent with findings on bZip proteins showing that interhelical salt bridges in heterodimers do not necessarily contribute favor-

ably to dimerization specificity and may indeed be unfavorable, when compared with alternative neutral charge interactions (35).

The consensus sequences for high affinity binding to MyoD and Id2 were quite similar. Likewise, the amino acids in many Zip region positions (2, 8, 11, 12, 16, 23, 25, and 26) showed the same preference for Rox or Mad binding, indicating that these positions *per se* are unable to determine specificity. Actually, it was shown previously that it is necessary to mutate four residues (residues 5, 12, 18, and 19) in the Myc Zip to overcome its inability to dimerize (6), that Id1 dimerization specificity can be conferred to E47 by replacing four amino acids at the helix 1/loop junction (36), and that a 6-fold increase in MyoD bHLH dimer stability is obtained by substituting 18 amino acids from the loop and the adjacent regions of E47 (33). Most of the mutants identified as binders show affinity for more than one protein. Thus, a domain recognition code, if it exists, must be rather tolerant. A strategy to increase specific binding to a particular partner would be to assemble and screen secondary libraries containing a larger number of mutations at a more restricted set of sites, such as those that we found most critical for molecular recognition. Altogether, these findings indicate that natural selection did not operate to maximize specific recognition between E-proteins and tissue-specific HLH, or between Max and the other bHLHZip of the network, but rather to guarantee that these proteins have a broad recognition spectrum to ensure effective binding to their HLH or HLHZip partners. Unnecessarily high affinity for a partner may represent an undesirable property, from an ev-

TABLE I
Amino acid frequency profile of affinity-selected HLH domains

	1	3	5	6	7	9	11	12	22	23	25	27	32	34	39
Repertoire	I L	V L H Q E D	L F	D K E N	A T N E K D	G R E K	M V L F G I	C G S F A I V T	Q L	T S F	L I V	T I	K I V E	V F Y D	Q P A E
E proteins	I	E_S	F	K_R	E	G	M	C_V	Q	T	L	I	V	V	E
Id2	strong binders	I _V	V _L Q	L _F	D _K E N	T _N A	G _K	M _V	C _G S	Q	T	L _I T _I	K _I V	V _Y	Q _P
	weak binders	I _V L	V _L	L _F	D _N K	E _D A K	R _E G	M _V L	C _G	Q	T _S	L _I V	T _I	K _I E	V _Y D F
MyoD	strong binders	I _V	V _L Q	L _F	N _K E D	T _N A	G _K	M _V	C _G S	Q	T	L _I T _I	K _I V	V _Y	Q _P
	weak binders	I _V L	V _L H	L _F	D _K E	N _E A K	G _R E	M _V L	C	Q	T _S	L _I V	T _I	K _I V E	V _D F
Random clones	L L I	E D H	L L F	D K D	E N E	G G G	M V M	C G C	Q Q Q	T S T	L V V	I I T	E V K	V D Y	P E E

TABLE II
Zip region amino acid frequency profile of affinity-selected bHLHZip domains

	2e	4g	5a	8d	9e	11g	12a	16e	18g	19a	23e	25g	26a	
Repertoire	R E Q G	K Q N E D H	E D K N	H L	I L R Q K	D I N V H L E Q K	E V I K	Q R K	Q E K R G	H S R N Q K	L Q M K E V	K R Q	L I V	
Max proteins	R	K	N_I	H_N	Q	D	I	K	Q	N_E	Q	V_I		
Mad	strong binders	Q _E R G	K _Q N	N _D K E	L _H	R L I	V N H D	V _E	Q _K R	E _Q R G	R _H S N	L K Q	K _R Q	I _L
	weak binders	Q _E R	K _N E	K _N E	H _L	R L	V D I L	V _E I	Q	R K Q E	R N Q S	E K Q M	R K Q	I _L V
Rox	strong binders	Q _E R	N K Q E	N K	L _H	L I R	V N D I L	V _I	Q _K R G E	N K Q S G	K L Q	R K I _L		
	weak binders	Q _E R	K N	N E K	H L	L R	D V L I	V _E I	Q	K Q E R	R Q S N	K Q E M	R K I _L V	
Random clones	Q Q Q	D E D	D D D	H H H	Q R Q	L Q V	V K V	Q K Q	R E R	Q R R	E M V	K Q Q	I I I	

olutionary standpoint, since it may diminish the reversibility of HLH(Zip) complex formation essential for cellular and developmental plasticity. The charged residues (e.g. the three

Glu residues in the HLH and His⁸ in the Zip) may be critical for providing such function.

On the other hand, a mutant domain with a higher affinity

for a partner can be exploited for functional interference (6, 7). Therefore the phage libraries described in this work represent a valuable collection of reagents and can be used for the selection of HLH and bHLHZip domains with novel recognition properties, to be employed for molecular dissection of the pathways involving HLH transcriptional regulators. This possibility is made more appealing by recent findings that implicate HLH and HLHZip domains in direct interaction not only with proteins of the HLH family but also with other transcriptional regulators such as Miz-1 and JLP, which interact with Myc and Max, or GRIPE and Pip, which interacts with the E-proteins (37–40). Such interactions are biologically relevant and enrich the functional plasticity of HLH proteins. Furthermore, mutant domains may be valuable for designing therapeutic approaches to diseases in which cell differentiation or proliferation is perturbed as a consequence of a deregulated HLH protein function. In this context, the HLH domain may represent a target for antiangiogenic drug design, because the naturally occurring HLH proteins Id1 and Id3, as well as Myc, appear to be required for tumor-induced angiogenesis (41, 42). The domains that showed increased affinity for Id2 *versus* MyoD, such as 13I and others, are intriguing in view of the role of Id2 as an antagonist of multiple tumor suppressor proteins (43). More particularly, Id2 and Myc were shown to collaborate in overriding the tumor suppressor function of Rb in neuroblastomas, and it was suggested that it might be possible to restore Rb control on cell proliferation in tumor cells, by sequestering Id2 (44). As the 13I domain is able to bind intracellular Id2 (data not shown), it would be tempting to investigate its *in vivo* function or that of other domains with altered binding properties.

Acknowledgments—We thank Nicola Rizzo for technical assistance, Robert Eisenman, Germana Meroni, and Armando Felsani for GST fusion plasmids, Simona Panni and Giovanna Vaccarello for help with λ phage display technology, Barbara Brannetti and Richard Jucker for thoughtful advice, and Laura Soucek for discussions and for critical reading of the manuscript.

REFERENCES

- Massari, M. E., and Murre, C. (2000) *Mol. Cell. Biol.* **20**, 429–440
- Grandori, C., Cowley, S. M., James, L. P., and Eisenman, R. N. (2000) *Annu. Rev. Cell Dev. Biol.* **16**, 653–699
- Baudino, T. A., and Cleveland, J. L. (2001) *Mol. Cell. Biol.* **21**, 691–702
- Nesbit, C. E., Tersak, J. M., and Prochownik, E. V. (1999) *Oncogene* **18**, 3004–3016
- Nasi, S., Ciarapica, R., Jucker, R., Rosati, J., and Soucek, L. (2001) *FEBS Lett.* **490**, 153–162
- Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998) *Oncogene* **17**, 2463–2472
- Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002) *Cancer Res.* **62**, 3507–3510
- Panni, S., Dente, L., and Cesareni, G. (2002) *J. Biol. Chem.* **277**, 21666–21674
- Castagnoli, L., Zucconi, A., Quondam, M., Rossi, M., Vaccaro, P., Panni, S., Paoluzi, S., Santonico, E., Dente, L., and Cesareni, G. (2001) *Comb. Chem. High Throughput Screen* **4**, 121–133
- O'Connell, D., Becerril, B., Roy-Burman, A., Daws, M., and Marks, J. D. (2002) *J. Mol. Biol.* **321**, 49–56
- Santini, C., Brennan, D., Mennuni, C., Hoess, R. H., Nicosia, A., Cortese, R., and Luzzago, A. (1998) *J. Mol. Biol.* **282**, 125–135
- Santi, E., Capone, S., Mennuni, C., Lahm, A., Tramontano, A., Luzzago, A., and Nicosia, A. (2000) *J. Mol. Biol.* **296**, 497–508
- Hoess, R. H. (2002) *Curr. Pharm. Biotechnol.* **3**, 23–28
- Felici, F., Castagnoli, L., Musacchio, A., Jappelli, R., and Cesareni, G. (1991) *J. Mol. Biol.* **222**, 301–310
- Saggio, I., Gloaguen, I., and Laufer, R. (1995) *Gene* **152**, 35–39
- Cicchini, C., Ansuini, H., Amicone, L., Alonzi, T., Nicosia, A., Cortese, R., Tripodi, M., and Luzzago, A. (2002) *J. Mol. Biol.* **322**, 697
- Ferre-D'Amare, A. R., Prendergast, G. C., Ziff, E. B., and Burley, S. K. (1993) *Nature* **363**, 38–45
- Brownlie, P., Ceska, T., Lamers, M., Romier, C., Stier, G., Teo, H., and Suck, D. (1997) *Structure* **5**, 509–520
- Ellenberger, T., Fass, D., Arnaud, M., and Harrison, S. C. (1994) *Genes Dev.* **8**, 970–980
- Ferre-D'Amare, A. R., Pognonec, P., Roeder, R. G., and Burley, S. K. (1994) *EMBO J.* **13**, 180–189
- Ma, P. C., Rould, M. A., Weintraub, H., and Pabo, C. O. (1994) *Cell* **77**, 451–459
- Shimizu, T., Toumoto, A., Ihara, K., Shimizu, M., Kyogoku, Y., Ogawa, N., Oshima, Y., and Hakoshima, T. (1997) *EMBO J.* **16**, 4689–4697
- Parraga, A., Bellolell, L., Ferre-D'Amare, A. R., and Burley, S. K. (1998) *Structure* **6**, 661–672
- Amati, B., Brooks, M. W., Levy, N., Littlewood, T. D., Evan, G. I., and Land, H. (1993) *Cell* **72**, 233–245
- Muhle-Goll, C., Gibson, T., Schuck, P., Schubert, D., Nalis, D., Nilges, M., and Pastore, A. (1994) *Biochemistry* **33**, 11296–11306
- Lavigne, P., Crump, M. P., Gagne, S. M., Hodges, R. S., Kay, C. M., and Sykes, B. D. (1998) *J. Mol. Biol.* **281**, 165–181
- Hu, Y. F., Luscher, B., Admon, A., Mermod, N., and Tjian, R. (1990) *Genes Dev.* **4**, 1741–1752
- Voronova, A., and Baltimore, D. (1990) *Proc. Natl. Acad. Sci. U. S. A.* **87**, 4722–4726
- Goldfarb, A. N., Lewandowska, K., and Shoham, M. (1996) *J. Biol. Chem.* **271**, 2683–2688
- Chavali, G. B., Vijayalakshmi, C., and Salunke, D. M. (2001) *Proteins* **42**, 471–480
- Tchan, M. C., and Weiss, A. S. (2001) *FEBS Lett.* **509**, 177–180
- Tchan, M. C., Choy, K. J., Mackay, J. P., Lyons, A. T., Bains, N. P., and Weiss, A. S. (2000) *J. Biol. Chem.* **275**, 37454–37461
- Wendt, H., Thomas, R. M., and Ellenberger, T. (1998) *J. Biol. Chem.* **273**, 5735–5743
- Shirakata, M., Friedman, F. K., Wei, Q., and Paterson, B. M. (1993) *Genes Dev.* **7**, 2456–2470
- Lumb, K. J., and Kim, P. S. (1995) *Science* **268**, 436–439
- Pesce, S., and Benezra, R. (1993) *Mol. Cell. Biol.* **13**, 7874–7880
- Schneider, A., Peukert, K., Eilers, M., and Hanel, F. (1997) *Curr. Top. Microbiol. Immunol.* **224**, 137–146
- Lee, C. M., Onesime, D., Reddy, C. D., Dhanasekaran, N., and Reddy, E. P. (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99**, 14189–14194
- Nagulapalli, S., Goheer, A., Pitt, L., McIntosh, L. P., and Atchison, M. L. (2002) *Mol. Cell. Biol.* **22**, 7337–7350
- Heng, J. I., and Tan, S. S. (2002) *J. Biol. Chem.* **277**, 43152–43159
- Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O'Reilly, R., Bader, B. L., Hynes, R. O., Zhuang, Y., Manova, K., and Benezra, R. (1999) *Nature* **401**, 670–677
- Baudino, T. A., McKay, C., Penderville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., and Cleveland, J. L. (2002) *Genes Dev.* **16**, 2530–2543
- Lasorella, A., Iavarone, A., and Israel, M. A. (1996) *Mol. Cell. Biol.* **16**, 2570–2578
- Lasorella, A., Nosedà, M., Beyna, M., Yokota, Y., and Iavarone, A. (2000) *Nature* **407**, 592–598

Molecular Recognition in Helix-Loop-Helix and Helix-Loop-Helix-Leucine Zipper Domains: DESIGN OF REPERTOIRES AND SELECTION OF HIGH AFFINITY LIGANDS FOR NATURAL PROTEINS

Roberta Ciarapica, Jessica Rosati, Gianni Cesareni and Sergio Nasi

J. Biol. Chem. 2003, 278:12182-12190.

doi: 10.1074/jbc.M211991200 originally published online January 3, 2003

Access the most updated version of this article at doi: [10.1074/jbc.M211991200](https://doi.org/10.1074/jbc.M211991200)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 44 references, 19 of which can be accessed free at <http://www.jbc.org/content/278/14/12182.full.html#ref-list-1>